Literature DB >> 25096614

Camptothecin and its analogs reduce amyloid-β production and amyloid-β42-induced IL-1β production.

Ju Wang1, Zi-Qi Shi1, Mu Zhang1, Gui-Zhong Xin1, Tao Pang1, Ping Zhou1, Jun Chen1, Lian-Wen Qi1, Hua Yang1, Xiaojun Xu1, Ping Li1.   

Abstract

Compounds derived from natural products are becoming promising alternative drugs/tools in Alzheimer's disease (AD) therapeutics. From an in-house natural products library, seventeen hits were selected for their inhibitory effect on the production of amyloid-β (Aβ) with IC50 lower than 10 μM without causing obvious toxicity. Among these compounds, camptothecin (CPT) and its analogs showed inhibitory effects on amyloid-β 1-42 (Aβ42) with the IC50 value in the nanomolar range in HEKsw cells and SHSY5Ysw cells. Further studies showed that CPT and its analogs inhibited Aβ42 via a p53 dependent pathway. Meanwhile, CPT and its analogs could also inhibit Aβ42 induced IL-1β production in the THP-1 cells. Taken together, our results indicate that CPT and its analogs would be a promising therapeutic candidates for AD.

Entities:  

Keywords:  Alzheimer's disease; IL-1β; amyloid-β; camptothecin; p53

Mesh:

Substances:

Year:  2015        PMID: 25096614     DOI: 10.3233/JAD-140078

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  2 in total

1.  Juglanthraquinone C Induces Intracellular ROS Increase and Apoptosis by Activating the Akt/Foxo Signal Pathway in HCC Cells.

Authors:  Ya-Qin Hou; Yao Yao; Yong-Li Bao; Zhen-Bo Song; Cheng Yang; Xiu-Li Gao; Wen-Jing Zhang; Lu-Guo Sun; Chun-Lei Yu; Yan-Xin Huang; Guan-Nan Wang; Yu-Xin Li
Journal:  Oxid Med Cell Longev       Date:  2015-11-22       Impact factor: 6.543

2.  Jujuboside A promotes Aβ clearance and ameliorates cognitive deficiency in Alzheimer's disease through activating Axl/HSP90/PPARγ pathway.

Authors:  Mu Zhang; Cheng Qian; Zu-Guo Zheng; Fei Qian; Yanyan Wang; Pyone Myat Thu; Xin Zhang; Yaping Zhou; Lifan Tu; Qingling Liu; Hui-Jun Li; Hua Yang; Ping Li; Xiaojun Xu
Journal:  Theranostics       Date:  2018-07-30       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.